21 June 2017 - FDA Commissioner Gottlieb talks about push before Senate panel.

For years, doctors have identified cancers by the affected body part: lung, breast, kidney. Now, in a long-awaited move, U.S. drug regulators will simplify the approval of treatments targeting specific gene mutations that can spur tumors in a variety of organs.

The FDA will soon announce a plan to update agency policies and facilitate the approval of critically needed drugs, including so-called “tumour-agnostic” therapies that target cancer-linked DNA, according to FDA Commissioner Scott Gottlieb.

Read Bloomberg article